🔴 Precigen is trading 5% down in pre-market on November 5 amid newly approved PAPZIMEOS rival

Precigen is trading at $4.80, down 5.04%, amid concerns over a newly approved rival for PAPZIMEOS.

• Q3 revenue was $74.1 million, net income was $35.8 million, and cash flow was positive ahead of guidance.
• PAPZIMEOS sales grew 37% sequentially; results were strong.
• Biotech rose 2.08% pre-market, so sector weakness does not explain the decline; no specific new negative earnings result was identified.